首页> 美国卫生研究院文献>Breast Cancer Research : BCR >Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

【2h】

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

机译：口服节律性长春瑞滨联合内分泌治疗激素受体阳性HER2阴性乳腺癌：SOLTI-1501 VENTANA机会试验窗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely addressed.

机译：背景口服节律性长春瑞滨（mVNB）单独或与内分泌疗法联合使用对激素受体阳性（HR +）/ HER2阴性乳腺癌患者的生物学效应几乎未得到解决。

著录项

期刊名称 Breast Cancer Research : BCR
作者
Barbara Adamo; Meritxell Bellet; Laia Paré; Tomás Pascual; Maria Vidal; José A. Pérez Fidalgo; Salvador Blanch; Noelia Martinez; Laura Murillo; Patricia Gómez-Pardo; Ana López-González; Kepa Amillano; Jordi Canes; Patricia Galván; Blanca González-Farré; Xavier González; Patricia Villagrasa; Eva Ciruelos; Aleix Prat;
展开▼
作者单位

展开▼
年(卷),期 2019(21),-1
年度 2019
页码 108
总页数 12
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Breast cancer Metronomic Vinorelbine Letrozole Window of opportunity Gene expression;

机译：乳腺癌;基因组学;长春瑞滨;来曲唑;机会之窗;基因表达;

相似文献

外文文献
中文文献
专利

1. A PHASE II STUDY OF METRONOMIC DAILY ORAL VINORELBINE AS FIRST-LINE CHEMOTHERAPY IN ADVANCED/METASTATIC HORMONE RECEPTOR POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) BREAST CANCER RESISTANT TO ENDOCRINE THERAPY: VINOMETRO [J] . Thomssen Christoph, Decker Thomas, Fehm Tanja, The Breast : . 2017,第Suppla1期

机译：II研究对群体每日口服血红素的研究，作为先进/转移激素受体的一线化疗阳性（HR加）/人表皮生长因子受体2阴性（HER2-）乳腺癌对内分泌治疗：VINOFORGRO
2. A PHASE II STUDY OF METRONOMIC DAILY ORAL VINORELBINE AS FIRST-LINE CHEMOTHERAPY IN ADVANCED/METASTATIC HORMONE RECEPTOR POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) BREAST CANCER RESISTANT TO ENDOCRINE THERAPY: VINOMETRO [J] . Thomssen Christoph, Decker Thomas, Fehm Tanja, The Breast : . 2017,第Suppla1期

机译：II研究对群体每日口服血红素的研究，作为先进/转移激素受体的一线化疗阳性（HR加）/人表皮生长因子受体2阴性（HER2-）乳腺癌对内分泌治疗：VINOFORGRO
3. A Phase II Study of Metronomic Daily Oral Vinorelbine as First-Line Chemotherapy in Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer Resistant to Endocrine Therapy: Vinometro [J] . Christoph Thomssen, Thomas Decker, Tanja Fehm, The Breast : . 2017,第期

机译：II研究衡量日常口服血红素的研究作为先进/转移激素受体阳性（HR +）/人表皮生长因子受体2阴性（HER2-）乳腺癌对内分泌治疗的一线化疗：VINOMETRO
4. Italian Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group Trials [C] . F. Boccardo, A. Rubagotti, D. Amoroso, International Conference on "Adjuvant Therapy of Primary Breast Cancer" . 1998

机译：意大利乳腺癌辅助化疗化学 - 激素治疗合作团体试验
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Molecular profiling of hormone receptor-positive HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609) [O] . Xu Liang, Adrien Briaux, Véronique Becette, 2018

机译：CARMINA 02试验中来自接受新辅助内分泌治疗的患者的激素受体阳性HER2阴性乳腺癌的分子谱分析（UCBG-0609）
7. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609) [O] . Xu Liang, Adrien Briaux, Véronique Becette, 2018

机译：来自患有新辅助内分泌治疗的激素受体阳性，HER2阴性乳腺癌在Carmina 02试验中的患者分子分析（UCBG-0609）

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

摘要

著录项

相似文献

相关主题

期刊订阅